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Abstract: In 2008, an estimated 33.4 million people were infected with human immunodeficiency 
virus (HIV) and ∼4 million people were receiving antiretroviral therapy (ART). However, in 2007, 
an estimated 6.7 million people were in need of ART under the current World Health Organization 
guidelines, and 2.7 million more people became infected with HIV . Most of those not currently 
eligible for ART will become eligible within the next decade, making the current treatment 
strategy unsustainable. The development of cheaper, less toxic, and more potent antiretrovirals 
over the past decade has made it possible to consider novel strategies of arresting the HIV/AIDS 
epidemic. Evidence is growing that ART can be used to prevent HIV transmission and that earlier 
initiation of treatment is beneficial for those infected with HIV . A mathematical model predicts 
that by testing whole communities annually and treating all who are infected immediately, up 
to 7.2 million AIDS-related deaths could be prevented in the next 40 years, long-term funding 
required to fight the HIV epidemic could be reduced, and, most importantly, control of the HIV/
AIDS epidemic could be regained within 1–2 years of full-scale implementation of the strategy. 
We discuss the development of the concept of ART for the prevention of HIV transmission and 
the modeled impact that a test-and-treat strategy could have on the HIV epidemic, and conse-
quently argue that a field trial should be carried out to confirm model parameters, highlight any 
practical problems, and test the model’s predictions.
Keywords: human immunodeficiency virus (HIV), test-and-treat, mathematical model, 
transmission, prevention, elimination
Introduction
In 2008, an estimated 33.4 million people were living with human immunodeficiency 
virus (HIV), and the number of new infections reached 2.7 million.1 It has been suggested 
that unless HIV transmission is stopped now, the targets of universal access to treatment 
and care will not be achieved.2,3 Various interventions, including behavior change through 
education, condom promotion, treatment of sexually transmitted infections (STIs), 
needle exchange programs, voluntary counseling and testing, and male circumcision, 
have been implemented in an attempt to stop the expansion of the HIV epidemic. 
Most have shown promise, but low uptake, poor adherence, and slow rollout have 
often frustrated the best efforts of public health authorities.4–8 Even the more effective 
interventions, such as male circumcision, which offers a 40% reduction in transmission 
at the population level, could not, by themselves, reduce HIV incidence sufficiently 
to rein in the epidemic completely.9 Only recently has a tenofovir-containing vaginal 
microbicide gel been shown to provide some protection to women.10 The development 
of an HIV vaccine remains a distant hope in spite of recent progress.11,12HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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New approaches are needed if the epidemic is to be 
stopped, and there has been renewed interest in the possibility 
of universal voluntary HIV testing with immediate treatment 
(test-and-treat) for the prevention of HIV transmission.13–15 
This would typically involve, in high prevalence settings, 
annual testing of presumptively HIV-negative people, together 
with the subsequent offering of immediate   antiretroviral 
therapy (ART) and appropriate follow-up to all people infected 
with HIV . Those found to be HIV positive and placed on treat-
ment (particularly acutely infected patients and patients with 
unstable viral loads) would require more frequent testing to 
monitor treatment adherence and provide early warning of 
the development of possible drug resistance. By placing all 
those infected with HIV on ART, as opposed to just those who 
meet current clinically defined stages of disease or who have 
a CD4+ count below 350 cells/µL, it has been estimated that 
transmission would be dramatically reduced.16,17 The intention 
of such a strategy, made possible through the development 
of cheaper, more effective, and less toxic drug regimens over 
the last decade,15,18–20 would be to stop transmission from 
infected to noninfected individuals and consequently drive 
HIV incidence rapidly toward zero.
ART dramatically reduces mortality in people living 
with HIV ,21–23 but the potential for ART to reduce trans-
mission is less certain.15,24–26 Given that ART, when taken 
as recommended, reduces viral load by several orders of 
magnitude,27–29 it shows promise as a means of reducing 
transmission. The population-level impact on transmission is 
still to be established, though. We review here the evidence 
for and against the use of a test-and-treat strategy for the 
prevention of transmission of HIV . We discuss the potential 
population-level impact and questions pertaining to testing 
frequency, timing of treatment initiation for those testing 
positive, and the tradeoff between high short-term costs and 
potential long-term savings resulting from implementation of 
mass HIV testing and treatment.16 We also discuss concerns 
that have been raised in the literature and conclude that 
there is an urgent need for a field trial to further evaluate the 
plausibility of such a strategy.
ART for prevention
The biological plausibility of using ART for the prevention 
of HIV transmission stems from the facts that transmission 
of HIV from infected to uninfected people takes place largely 
through exposure to bodily fluids,30–32 that viral load in these 
fluids largely determines the risk of transmission,33,34 and 
that the use of ART has been shown to reduce HIV-1 RNA 
concentration in both blood and seminal plasma by up to 
six orders of magnitude.16,28,29,35–37 Furthermore, as the viral 
load in blood plasma is correlated with the viral load in semen 
and vaginal secretions,38 ART also reduces the concentration 
of HIV-1 RNA in the female genital tract.39
Proof of concept comes from the fact that mother-to-
child (MTC) transmission has virtually been eliminated in 
  developed countries, where universal voluntary HIV testing 
and ART provision are now commonplace.40,41 Maternal 
plasma HIV-1 RNA concentration has long been recognized 
as the major determinant of MTC HIV transmission,42 
so prevention of vertical transmission has been made possible 
by reducing the viral loads of HIV-positive mothers through 
the widespread distribution and use of ART.43,44
If ART is to have a similar impact on the overall HIV 
  epidemic, it must prevent the most predominant form of 
transmission, namely heterosexual transmission. Studies 
in Thailand and Uganda have shown that transmission 
in   heterosexual, HIV-serodiscordant couples depends 
strongly on the viral load within the infected partner, 
and no   transmission events were observed when the 
infected person had an HIV-1 RNA plasma concentration 
of ,1000   copies/mL.33,45   Similarly, a third study reported that 
viral load and positive viral isolation in culture were both risk 
factors for heterosexual transmission of HIV-1.46 In Spain, 
transmission decreased by 86% in those   heterosexual, 
  serodiscordant couples where the infected person was on 
ART.47 Similar results were obtained in Italy, before triple 
therapy became available, where zidovudine monotherapy 
was found to reduce transmission by 50%.48 These results 
suggest that mass rollout of ART could be used to effect 
major reductions in heterosexual transmission.
The mass rollout of ART for prevention has nonethe-
less been received with some skepticism. Of particular 
concern is the possibility that behavioral disinhibition 
among those on ART will increase their risk of infection 
and nullify the benefits of treatment.49–51 Several modeling 
studies have suggested that even modest increases in 
risky behavior would be sufficient to negate any potential 
decrease in HIV incidence.24,52–54 However, if ART reduces 
transmission by 10 times or more, behavioral disinhibition 
would have to increase transmission by 10 times or more, 
which is unlikely, and there is evidence that these fears may 
be exaggerated. In Taiwan, where policy was adopted in 
1997 to provide every person living with HIV free access 
to ART, a   population-level decrease in transmission of 
53% was observed by 2002.55 The incidence of syphilis, 
used as a marker for behavioral risk compensation during 
this period, remained unchanged.55 Similar results have HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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also been reported for British Columbia, where new HIV 
  infections between 1995 and 1998 decreased by 50%, 
despite an increase in syphilis rates.15 A review of 25 studies 
  including heterosexual men and women,   homosexual men, 
and   intravenous drug users, furthermore showed no overall 
increase in risky sexual behavior among those receiving 
ART, even when therapy achieved an undetectable viral 
load.56 In Africa, ART has been associated with a decrease 
in risky sexual behavior. In Uganda, starting people on ART 
reduced the likelihood that they would engage in risky sexual 
behavior by as much as 50%–70%.25,57 A 7-year study in 
South Africa also found that after ART initiation, people had 
less unprotected sex and fewer concurrent sexual partners.58 
It has been suggested that the widespread provision of ART 
may result in increased contact between health care providers 
and treated patients, facilitating greater opportunity to 
encourage safe sexual practices, which would further rein-
force prevention efforts.56,59 This evidence suggests that ART 
for prevention should be seriously reconsidered.
Under current guidelines, ART is administered on 
immunologically and clinically defined disease status, with 
the focus being the reduction of morbidity and mortality.17 
Consequently, ART is generally given only to those whose 
immune system is already severely compromised.16,60 The 
extended length of time it takes for a patient’s CD4+ count to 
fall below the recommended threshold for treatment initiation 
means that an infected person’s period of infectivity is very 
long, so ample opportunity exists during which transmission 
may take place.3 Ignorance of HIV status, as well as low treat-
ment coverage, further exacerbates the situation.2,3,61,62 The 
current strategy is therefore not able to reduce transmission, 
even if perfect implementation was possible.
Along with reducing transmission, the evidence is that 
early treatment also improves the prognosis for the treated 
individual. Early treatment was first advocated by Ho,63 
mainly in relation to the potential benefit for infected 
  individuals, because of the following reasons. First, the viral 
population in newly infected cases tends to be homogeneous, 
making it less likely to contain drug-resistant variants and 
therefore more susceptible to effective treatment regimens. 
Second, the number of virions produced during a single 
month of acute infection approximates the number produced 
during several years of asymptomatic chronic infection, so 
treatment just after seroconversion may be more efficient and 
could therefore have a greater effect than delayed treatment. 
Third, the plateau concentration of plasma viral RNA has 
been shown to be predictive of the long-term clinical outcome 
of an infected individual, so by treating patients soon after 
seroconversion, the initial set point viral load could be 
lowered and the clinical outcome thereby improved.63
Further individual benefit of early treatment initiation 
derives from the fact that uncontrolled HIV replication 
appears to contribute to non-AIDS-defining complications, 
including disease of the liver, kidney, and cardiovascular 
system and non-AIDS malignancies.64 Earlier treatment of 
HIV-infected patients could serve to reduce the frequency of 
occurrence of such complications, subsequently improving 
the general health of infected individuals. In Zimbabwe, 
increased rates of mortality among HIV-positive postpartum 
women, compared with those who are HIV negative, along 
with identified causes of death, suggest that early initiation 
of ART could prevent 50%−90% of deaths in HIV-positive 
postpartum women.65 In particular, this was true for post-
partum women who would not qualify for ART under the 
current ART treatment guideline of a CD4+ count below 
350 cells/µL.65
A further argument for the use of ART for prevention 
was provided by Montaner et al, who used UNAIDS regional 
statistics to show that the ratio of new HIV infections to 
prevalent cases correlated inversely to the availability of 
ART in each region.15 The effect of ART on transmission 
was subsequently estimated for those regions where ART 
was widely available. Using the same methodology as that 
presented by Montaner et al, one would expect between 1.2 
and 2 million new infections to be prevented annually by 
mass rollout of ART in those areas where incidence is .8% 
of prevalence. This equates to a total long-term saving of 
US$296−493 billion in treatment costs, based on the same 
estimated cost for lifetime treatment of US$241,000 used 
by Montaner et al.15 The limitations of this kind of argument 
include the unknown accuracy of regional   incidence and prev-
alence data, the assumption that the number of transmitted 
cases was directly proportional to the   number of prevalent 
cases, and the fact that ART may be only one of several fac-
tors contributing to the lower incidence to prevalence ratios 
seen in some regions. Nevertheless, it offers a glimpse of the 
potential impact ART may have on HIV transmission in those 
areas where ART is still not   readily available, as well as the 
possible financial savings that could accompany it.
The modeled impact of ART  
for prevention
Given the established potential for ART to prevent HIV 
  transmission and the failure of current interventions to 
  produce significant reductions in HIV incidence, Granich et al 
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Dovepress 
Dovepress
12
Johnstone-Robertson et al
have on the HIV epidemic.16 The strategy would involve 
diagnosing all those infected with HIV as soon as possible 
after infection and immediately offering ART to all who 
test positive. Its impact was modeled in the context of a 
generalized heterosexual epidemic, with a magnitude similar 
to that found in southern Africa, and was described in terms 
of the expected decrease in incidence.
Stochastic model
When any intervention is implemented, the hope is that 
  incidence will be sufficiently reduced to eliminate the 
epidemic. Granich et al defined elimination as incidence 
of ,1 HIV infection per 1000 people per year,16 which would 
require that the basic reproductive number R0 (the number of 
  secondary infections resulting when a single infectious case 
is introduced into a completely susceptible population) be 
reduced to, and kept, below 1.66 Granich et al constructed a 
stochastic model to determine how frequently people would 
have to be tested for HIV infection and how soon after test-
ing positive they would need to be placed on treatment, so 
that R0 could be brought below unity and the HIV epidemic 
eliminated.
After calibrating the stochastic model to a South Afri-
can epidemic, where R0 = 7 prior to the introduction of 
ART,67 the amount by which R0 would decrease was shown 
to depend on both testing frequency and CD4+ count at 
which ART would be started in those testing HIV positive. 
It was shown that for R0 to be brought below 1, universal 
voluntary HIV testing would have to be conducted at least 
once a year and ART would have to be initiated, at the 
latest, when an infected person’s CD4+ count drops below 
900 cells/µL. Because the mean CD4+ count immediately 
after seroconversion in South Africa is just below 900 cells/
µL,67 ART would effectively have to be initiated as soon 
as possible after diagnosis. Anything short of this and the 
basic reproductive number will remain above 1, resulting 
in an epidemic that persists.
Deterministic transmission model
The time-dependent impact of the test-and-treat strategy 
on the South African HIV epidemic was modeled using 
an ordinary differential equation (ODE) deterministic 
transmission model. In particular, the impact it would have 
was compared with that expected for the current strategy, 
where ART should be initiated when an infected person’s 
CD4+ count falls below 350 cells/µL. The authors calculated 
the number of deaths averted and the funding required for 
each strategy and compared the latter with UNAIDS estimates 
of global funding needed for universal access to be achieved. 
They also estimated the time for elimination to be achieved 
after implementation of the test-and-treat strategy.
Once the deterministic transmission model was calibrated 
to South African national antenatal clinic prevalence data 
for people aged 15 years and above, ART was introduced 
in order to determine the impact it would have on a 
  predominantly heterosexual epidemic. Under the current 
strategy of starting ART once CD4+ count falls below 
350 cells/µL, the incidence and prevalence of those not on 
ART decreased by ∼30%. Mortality decreased by an even 
greater margin because everyone, apart from those who 
refused treatment, started ART when their CD4+ cell count 
fell below this level.16 The rate at which people started ART 
and the mortality of those on ART were shown to peak at 
0.08%/year in 2014 and 0.8%/year in 2020, respectively. 
The proportion of people on ART would be expected to 
reach a maximum of 5% in 2020.
Introducing ART, at the intensity prescribed by the 
stochastic model for the test-and-treat strategy, illustrated 
that such a strategy would reduce the incidence, prevalence, 
and mortality of those not on ART to negligible levels. The 
rate at which people would be placed on ART is expected 
to increase and peak at 0.5%/year in 2010, which reflects 
the fact that every HIV-infected person would be eligible 
for treatment. All those receiving ART would require 
treatment until the end of their natural lives, however, 
so that the proportion of people on ART would increase and 
peak at around 12% in 2014. In spite of this, by 2016, there 
would be fewer people starting ART, and by 2030 fewer 
people receiving ART, than there would be with the current 
strategy. This would be a direct result of the ART-associated 
reduction in transmission. Mortality of those on ART was 
similar until 2016 for the two strategies, when mortality for 
the test-and-treat strategy is expected to reach its peak at 
0.5%/year and subsequently start to decline, whereas that 
of the current strategy would continue to rise considerably 
for at least another 5 years.
The most important result of any intervention is the 
number of lives that can be expected to be saved.   Excluding 
all forms of intervention from the ODE model, it was 
  estimated that just over 11 million AIDS-related deaths would 
occur between 2008 and 2050. By including the   current 
treatment strategy of ART for those infected individuals 
whose CD4+ count is below 350 cells/µL in the ODE model, 
this number could be reduced to 8.6 million, so 2.4 million 
lives would be saved. Under the test-and-treat strategy, the 
number of AIDS-related deaths averted in the same time HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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period was estimated at 7.2 million, so fewer than 4 million 
HIV-related deaths would occur in the next four decades.
The time required for the HIV epidemic to be eliminated, 
after rollout of the test-and-treat strategy, was found to depend 
on both the starting time of the rollout and the rate at which 
rollout takes place. If rollout had begun in 2008, and had 
been fully scaled up by 2016, elimination would have been 
achieved by 2014, ie, within 6 years of the strategy being 
started. The time to elimination is an important aspect of the 
intervention because it informs policy makers when they can 
expect to start   seeing a return on their investment, in the form 
of   savings in treatment costs resulting from reduced numbers of 
people being treated. Moreover, it informs health providers of 
how long it will be before focus has to be shifted from preven-
tion of transmission to management of people already infected. 
Finally, it is important epidemiologically because it indicates 
the time until the epidemic is brought under control.
Granich et al calculated the potential costs of both the test-
and-treat and the current strategy and compared them with 
the UNAIDS estimate of funds needed to provide universal 
access to prevention, care, and treatment in South Africa, 
where 17% of the global HIV/AIDS burden exists.1,16,68 It was 
assumed that first-line and second-line therapy would cost 
US$727/year and US$3290/year, respectively, both of which 
would include drug delivery, HIV and laboratory testing, and 
patient management. The model indicated that   test-and-treat 
would initially be about three times as expensive as the current 
  strategy, costing US$3.4 billion in 2015. Thereafter, however, 
the cost of the test-and-treat strategy would decline, whereas 
the current strategy would continue to rise as more people 
require ART. By 2034, the test-and-treat strategy would cost 
less annually than the current strategy. Furthermore, it would 
cost less than the US$8.84 billion/year estimated by UNAIDS 
to achieve universal access to prevention, care, and treatment 
in South Africa by 2015. These results are better than the 
initial   estimates proposed by Montaner et al in which the cost 
of treating all HIV-infected people in the first year, assum-
ing there would be no new infections   taking place afterward, 
amounted to an average annual cost of US$7 billion.15 In the 
short term the test-and-treat strategy will be costly, but in the 
long term it will be cost effective due to the huge number of 
infections that are prevented in years to come.
Universal voluntary HIV testing  
and immediate treatment:  
the challenges and benefits
Major challenges facing the implementation of the test-and-
treat strategy relate primarily to the sheer numbers involved, 
creating even greater obstacles than those seen in current 
ART scale-up programs, as many people infected with HIV 
would qualify for ART.15 Where health infrastructure is weak, 
it would need to be strengthened to cope with the increase in 
demand. Adequate training of health care workers, as well as 
ensuring the continuous supply of drugs and other resources, 
will form an integral part of this process. One suggested 
means of reducing the potential burden would initially be 
to focus mass HIV testing on the most-at-risk populations, 
namely those people infected with tuberculosis (TB) or 
sexually transmitted diseases, and pregnant women.69 It is 
important that rural populations not be neglected, though, and 
relevant ways of reaching these populations must therefore 
also be considered. Despite the expected increase in demand 
on health services, increased numbers of HIV-infected people 
having access to ART will result in a decrease in morbidity. 
This will go some way to alleviate the increased burden on 
health systems, freeing human resources and capacity in the 
long run.16 A clear programmatic advantage of the strategy 
is that there would be only one criterion for a person to be 
placed on treatment, namely HIV status. The fact that CD4+ 
cell count or viral load would not be considered would free 
up a significant amount of human and financial resources.
The success of the test-and-treat strategy will depend on 
its acceptability and uptake by the populations in which it 
is implemented. In the model presented by Granich et al, it 
was assumed that all adults in a community would be tested 
for HIV once a year, on average, and that those diagnosed 
as HIV positive would start ART immediately, irrespective 
of CD4+ cell count.16 A refusal rate was incorporated into 
the model to take into account those who refused treatment. 
High rates of acceptability and uptake will only realistically 
be possible through community education and awareness 
campaigns that encourage HIV testing. Even in a country 
such as the US, where HIV testing is widely available, 
25% of infected individuals still do not know their status;70 
the figure for Sub-Saharan Africa is 78%.2 The education 
and awareness campaigns could also be used to encourage 
uptake of   immediate treatment after testing so that refusal 
rates are kept to a minimum. Steps must also be taken to 
ensure that coercion is prevented and that the human rights 
of   individuals being tested and placed on treatment are 
protected. Appropriate training, engagement with the com-
munity, and supervision should be sufficient to keep such 
problems to a minimum.
Once patients have been tested and placed on treatment, 
there will be the challenge of managing patient adherence and 
change in risky behavior. Data from Malawi and elsewhere HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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indicate that good levels of adherence are achievable in both 
resource-limited settings and marginalized populations in 
developed countries, suggesting little reason to believe that 
adherence would be reduced if adequate patient support 
and treatment literacy are provided.71–73 Others have argued, 
however, that current data are indicative only of those seeking 
treatment because they are sick, whereas implementing the 
test-and-treat strategy would include placing on treatment those 
who still feel well, so the levels of adherence assumed in Gran-
ich et al’s model would be difficult to achieve.74 Either way, 
appropriate management of patient adherence will be neces-
sary practice to ensure the effectiveness of early treatment. 
With regard to behavioral risk   compensation, the evidence 
available indicates that it is unlikely to be important in Africa 
and other areas where heterosexual transmission is predomi-
nant.59 It has been suggested that as better contact between 
treated patients and their health care providers increases the 
opportunities for the prevention of secondary transmission, it 
may even be possible to decrease levels of risky behavior.59 
Behavior should nonetheless be monitored because the 
behavioral implications of a large cohort of people receiving 
ART is still uncertain.   Monitoring increases in risky behavior 
could be accomplished by observing changes in the rates of 
STIs,55 while simultaneously monitoring any potential for 
coinfection of HIV and STIs to re-establish the infectiousness 
of HIV patients on ART.59,74 Patient management will therefore 
play an important role in the test-and-treat strategy and will 
serve to ensure that risky behavior and STIs will not undermine 
the ability of ART to prevent transmission.
Drug regimens will form an integral part of the strategy 
of treatment for prevention. For the strategy to have the 
impact proposed, it will be necessary for the latest, most 
effective regimens to be accessible in all countries.70 Such 
regimens will need to be cheap and easy for patients to 
take and have low toxicity.16 First-line regimens such as 
these are now available, increasing the feasibility of the 
strategy.15,18,19,75 Potent second- and third-line regimens with 
similar characteristics will also be required so that if first-line 
drug resistance develops in patients, the regimens required 
to maintain viral load suppression will be readily available. 
Second-line regimens are currently still significantly more 
expensive than their first-line counterparts.16,20 Mass rollout 
of these drugs, however, can be expected to cause a drop in 
regimen prices as simpler and cheaper generic regimens are 
developed and as supply chains are strengthened. The choice 
of appropriate drug regimens and decisions on how they will 
be best administered operationally and clinically will need 
careful consideration prior to the start of any intervention. 
The approaches, moreover, are likely to vary with location 
and circumstance. In each case, the choice will need to be 
made in such a way as to ensure minimal side effects, low 
rates of failure, and maximal adherence.
Similarly, although the default approach will be to offer 
ART to all HIV-positive people, this decision would be in the 
hands of individual clinicians who could modify this decision 
on the basis of additional information on particular patients. 
Careful monitoring of patients will also be essential to ensure 
the early detection of any adverse events.
Drug resistance should be monitored closely and con-
tinuously on implementation of the test-and-treat strategy. 
Mathematical models initially predicted that transmitted 
resistance will increase with the proportion of HIV-infected 
people receiving ART.59 It has been reported, however, that 
drug-resistant HIV may be less transmissible than drug-
susceptible strains.76 There is also empirical evidence that the 
suppression of HIV RNA on a population level is associated 
with a decrease in drug resistance.77
The implementation of the test-and-treat strategy will pro-
duce a rapid decline in HIV incidence and mortality and thus 
a shift in focus, from ensuring that everyone infected is placed 
on treatment to managing patient adherence and   minimizing 
transmitted resistance.16 HIV prevalence would also decline, 
but only at a later stage, when the cohort receiving ART starts 
to age and die. Granich et al modeled an epidemic similar to 
that found in South Africa, where HIV prevalence is high. In 
low prevalence settings, it will not be efficient to test entire 
populations for HIV .16 The intensity and frequency with which 
such a strategy would need to be implemented will thus vary 
with the epidemiological context and cohort of patients being 
treated.3,74 The establishment of worldwide-accepted criteria 
of patients’ enrollment and monitoring in this regard is essen-
tial to the efficacy and success of such a strategy.
Despite the intensive screening implicit in the test-and-
treat strategy, it is likely that some HIV-infected people would 
still be missed, facilitating the persistence of small pockets 
of transmission among those with high risk.74 It is therefore 
important that the strategy initially focuses on those at high 
risk of infection as it is rolled out, so that these “transmission 
pockets” are kept to a minimum.
A concern that has been raised with respect to the pro-
posed strategy is whether or not it could be implemented in 
the face of widespread HIV-related stigma. It has even been 
suggested that the strategy could serve to increase stigma if 
partial success led to HIV becoming associated with   particular 
subpopulations.78 Others have argued that the opposite would 
in fact be true: that the strategy could play a significant part HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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in reducing HIV-related stigma by raising awareness of HIV 
and the drugs available for treatment and by encouraging 
HIV infection to be regarded in the same manner as any 
other infection.79 This, it was suggested, could go a long way 
to removing HIV-associated fear and discrimination. The 
potential for the strategy to shift the benefits of treatment from 
the individual to the general population was another concern 
that was raised. Growing evidence for the individual’s benefit 
of earlier treatment has, however, been established.
An important benefit of the test-and-treat strategy lies in 
its potential for significantly reducing coinfections;79,80 in par-
ticular, it may go a long way toward arresting the tuberculosis 
epidemic.81 Other potential benefits are likely to include 
decreased deaths resulting from late diagnosis, further 
prevention of MTC transmission, and the reinforcement of 
current efforts to provide universal access to ART.2,60,65
Conclusion
The mathematical model published by Granich et al indicates 
that the test-and-treat strategy could have a big impact on the 
HIV epidemic. In particular, it is estimated that the strategy 
could prevent up to 7.2 million AIDS-related deaths in the next 
40 years if implemented in conjunction with other interventions 
already in place. Such a strategy would require large initial 
financial investment but would become more cost effective than 
the current treatment strategy within 30 years of rollout. The 
immediate priority is a field trial aimed at addressing uncertain-
ties regarding model parameters and determining any practical 
issues that would need to be considered more carefully before 
large-scale implementation of the strategy can take place. A 
field trial would also serve to acquire the empirical data needed 
to guide national ART programs and would go a long way 
toward determining whether the test-and-treat strategy will have 
the impact on the HIV epidemic that has been modeled.
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